Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIM-Line Pilot: Rivaroxaban for CVC VTE Prophylaxis
NCT03506815Phase 3Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE) comparing Rivaroxaban Thromboprophylaxis with Standard of care (2 arms). Primary endpoint: Number of Participants Recruited Per Month at 12 months. Started Mar 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03506815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506815.